Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
Institute of Hematology & Blood Diseases Hospital, China
Peking University People's Hospital
M.D. Anderson Cancer Center
Ascentage Pharma Group Inc.
Institute of Hematology & Blood Diseases Hospital, China
Peking University People's Hospital
Ascentage Pharma Group Inc.
Ascentage Pharma Group Inc.
Ascentage Pharma Group Inc.
First Affiliated Hospital of Zhejiang University
Ascentage Pharma Group Inc.
Ascentage Pharma Group Inc.
Institute of Hematology & Blood Diseases Hospital, China
The First Affiliated Hospital of Soochow University
Shenzhen Second People's Hospital
Ascentage Pharma Group Inc.